Articles tagged with: NICE
News »
U.K. Agency Recommends Velcade and Thalidomide For Myeloma Patients – The National Institute of Clinical Excellence (NICE), the agency that decides which treatments will be funded for patients in England and Wales, released a final draft guidance on June 2 recommending that Velcade (bortezomib) and thalidomide (Thalomid) can be used as first-line treatments for multiple myeloma patients who are not candidates for stem cell transplants. Both drugs are currently recommended as second-line treatments. The final guidance deciding the use of Velcade and thalidomide in the U.K. is expected later this year. For more information, please see the NICE website.
15th Congress Of The European Hematology Association – As a reminder to Beacon readers, the European Hematology Association (EHA) will hold its 15th meeting from June 10 to 13 in Barcelona, Spain. European researchers and physicians will meet to present the latest research findings about multiple myeloma and other blood disorders. The Myeloma Beacon will also be covering the event on its website. For more information, please visit the EHA Congress website.
MMRF Race For Research – On June 13, the Multiple Myeloma Research Foundation (MMRF) will hold a Race For Research 5K Walk/Run in New Canaan, CT, to raise awareness and funds for multiple myeloma research. Registration is scheduled for 7:30 a.m., and the race starts at 9 a.m. For more information, please see the MMRF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News »
San Diego International Triathlon – On June 28, the 26th annual San Diego International Triathlon will begin at 5:15 a.m. and end at noon. The race will be held at Spanish Landing Park, and The Leukemia & Lymphoma Society’s Team In Training (TNT) will be participating. The race benefits St. Vincent de Paul Village, America’s top rehabilitation center for homeless and those in need. To join Team In Training for the triathlon, visit the TNT Web site.
The Price Of Life – Directed by Adam Wishart, this BBC documentary is the first to film the decision-making process of the National Institute for Health and Clinical Excellence (NICE). NICE is an independent organization that provides medical opinions to the National Health Service (NHS), the government-funded health care system in the U.K. The documentary gives insight into NICE’s process of deciding whether or not Revlimid (lenalidomide) should be approved for use and funded by the NHS. It also gives the perspective of patients and an American drug company. For more information, please visit BBC Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
Headline, News »
In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has finalized guidelines for the use of Revlimid (lenalidomide) in combination with dexamethasone (Decadron). The guidelines recommend the use of Revlimid for myeloma patients who have already received two or more prior therapies.
NICE is an independent organization that provides medical opinions to the National Health Service (NHS), the government-funded health care system in the U.K.
Based on NICE’s recommendation, the NHS will only pay for Revlimid for patients who have received at least two…
News »
On April 23, the National Institute for Health and Clinical Excellence (NICE) announced its final decision to recommend coverage of Revlimid (lenalidomide) in England and Wales. NICE has endorsed Revlimid in combination with dexamethasone (Decadron) for the treatment of multiple myeloma in patients who have already received prior therapies.
Revlimid is a therapeutic agent that has often proven to be effective in the treatment of relapsed patients. Clinical trials report extended survival times and recession in signs and symptoms in the majority of patients.
In the U.K., NICE…
News »
Multiple myeloma patients in England and Wales will now be able to receive Revlimid (lenalidomide) as a treatment option under the National Health System (NHS) after an agreement was reached between NHS and Celgene, the maker of Revlimid.
The news comes after Celgene proposed a new cost-sharing plan where the NHS will pay for the first two years of treatment, and Celgene will pick up the bill for any further treatment. It is estimated that approximately 17 percent of myeloma patients treated with Revlimid will require treatment after…
News »
The health care system in the United Kingdom is making more treatment options available to terminally ill patients.
In England and Wales, the National Institute for Health and Clinical Excellence (NICE) decides which treatments will be made available under the state-funded National Health Service. Until recently, NICE refused to approve the use of any drug costing more than £30,000 ($44,000) for each extra year of good health attributable to the drug.
On January 2, NICE issued new guidelines to approve, under certain circumstances, life-extending drugs that cost as much as…
News »
The health care system in England and Wales may soon stop funding the use of the drug Revlimid (lenalidomide) to treat multiple myeloma.
The agency responsible for controlling health care costs in those countries has issued a preliminary ruling that treating myeloma with Revlimid is not cost effective.
The agency – the National Institute for Health and Clinical Excellence (NICE) – admits that the drug is clinically effective. The once-a-day capsule has been shown to extend the lives of myeloma patients by nearly three years. As a result,…